Fig. 3
Tumors regressed with the combination treatment in a syngeneic mouse tumor model. CT26 cells (2 × 105 / mice) were subcutaneously injected into the backs of seven-week old Balb/c mice. A total of 60 mice were used in this experiment: 15 mice per group. ILz:rhTRAIL and/or bortezomib were injected via the tail vein every 2 days from 10 days after the injection of CT26 cells, when average tumor volume reached 40 mm3. The ‘sham control’ mice were injected with phosphate-buffered saline, ‘ILz:T’ mice were injected with ILz:rhTRAIL (10 μg/ kg), ‘ILz:T/bort’ mice were injected with ILz:rhTRAIL (10 μg/ kg) and bortezomib (3.8 μg/ kg), and ‘bort’ mice were injected with bortezomib (3.8 μg/ kg). Tumor volumes were measured from the day that CT26 cells were injected until mice were sacrificed. Mice were sacrificed 20 days after being injected with CT26 cells. The experimental time table is depicted in (a). (b) Average tumor volumes in each group prior to sacrifice are represented, which were recorded from day 10 to day 18. Statistical significance for the four groups was identified by ANOVA single test (p < 0.05). (c) Tumors were isolated and pictures taken before formalin fixation. Although seven mice were represented in each group, only five tumors were able to be isolated in the ‘ILz:rhTRAIL/bortezomib’ group because the other tumors had almost completely regressed